- Investor Relations Asia Pacific

WuXi Biologics (Cayman) Inc.
(Incorporated in the Cayman Islands with limited liability)

Press Releases       

Please download the latest "Acrobat Reader" to view the PDF.

  • 2022-March-22
  • WuXi Biologics Achieved Record Growth and Profitability in 2021, Banner Year for Commercial Manufacturing, Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million, Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million, Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million, Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million, Total Backlog Grew 20.1% to US$13,597 Million (in PDF)
  • 2021
  • 2021 Press Releases
  • 2020
  • 2020 Press Releases
  • 2019
  • 2019 Press Releases
  • 2018
  • 2018 Press Releases
  • 2017
  • 2017 Press Releases

  • Company's Index

  • About   |   Terms of Use   |   Privacy Policy Statement   |   Disclaimer
    © Copyright 1996-2024 Ltd. All rights reserved.
    DISCLAIMER: Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall Ltd. be liable for damages resulting from the use of the information provided on this website.
    Cookie Policy

    This website uses cookies. Please refer to our Cookie Notice and Privacy Notice for further information. By continuing to use this website, you agree to our use of cookies.